WCN26-5543 EFFICACY OF ATRASENTAN BY RENIN–ANGIOTENSIN SYSTEM INHIBITOR DOSE IN IgA NEPHROPATHY PATIENTS FROM EAST ASIA: POST HOC ANALYSIS FROM THE PHASE III ALIGN TRIAL

Introduction: Long-term clinical monitoring is essential in IgA nephropathy (IgAN) to detect disease progression and adjust therapy.However, a subset of patients voluntarily discontinues follow-up, and the characteristics of such patients remain unclear.This study aimed to clarify the characteristics of patients who discontinued follow-up.